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Abstract Cardiovascular disease remains the major cause
of worldwide morbidity and mortality. Its pathophysiology
is complex and multifactorial. Because the phenotype of
cardiovascular disease often shows a marked heritable
pattern, it is likely that genetic factors play an important
role. In recent years, large genome-wide association studies
have been conducted to decipher the molecular mechanisms
underlying this heritable and prevalent phenotype. The
emphasis of this review is on the recently identified 17
susceptibility loci for coronary artery disease. Implications
of their discovery for biology and clinical medicine are
discussed. A description of the landscape of human
genetics in the near future in the context of next-
generation sequence technologies is provided at the
conclusion of this review.
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Introduction
Cardiovascular disease (CVD) remains the major cause of
worldwide morbidity and mortality despite currently available
therapy. Full appreciation of all risk factors and the patho-
genesis of this disease are inevitably required to identify
additional targets for therapy. Atherosclerosis, the major
underlying cause of CVD, is present in all humans at
advancing age and progresses over a life time, but its extent
and progression is dependent on factors such as dyslipidemia,
hypertension, obesity, diabetes, and smoking [1]. In addition,
genetic factors play an important role. Twin studies indicate
that heritability of CVD, defined as the proportion of the
inter-individual differences resulting from genetic factors, is
30% to 60% [2]. This translates to the fact that apart from the
classical risk factors, a positive family history for premature
coronary artery disease (CAD) in a first-degree relative also
constitutes an additional and independent risk [3].
A large number of studies have aimed to decipher the
molecular mechanisms underlying the heritability of CVD;
however, in recent years the approach has seen major changes.
In early attempts, case–control studies focused on the differ-
ences in carrier frequency of genetic variations in “candidate
genes” among cases and controls. Genes were marked as
“candidate” based on the fact that they were known to influence
traditional risk factors (ie, genes involved in lipid metabolism)
or were part of pathways with a putative role in atherogenesis.
Later, a whole genome approach was applied to find
genetic variations without a prior hypothesis. Initial
attempts included classical linkage studies in families with
premature CAD using microsatellite markers and later
single nucleotide polymorphism (SNP) arrays for linkage
[4]. These early family-based studies have thus far resulted
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in the identification of two interesting candidate genes,
MEF2A and LRP6.
Through linkage analysis in an extended kindred that
displayed an autosomal dominant pattern of CAD, a large
locus containing 93 genes was identified on 15q26 [5].
Within this locus, the gene for myocyte enhancer factor 2
(MEF2A) was considered the best candidate for further
investigation, because of its previously described effect on
myocardial development and vascular morphogenesis [5].
Interestingly, a number of genetic variants in MEF2A were
identified in other small cohorts of patients with CAD,
suggesting that MEF2A may be actively involved in
atherosclerosis [6]. Recently, however, additional studies
have not revealed any evidence for a role of MEF2A as a
susceptibility gene for CAD, thereby refuting the original
hypothesis [7, 8]. Novel missense mutations in MEF2Awere
identified, but in vitro expression of the mutant proteins did
not show a difference in transcriptional activity. Thus, the
support for a role for MEF2A in CVD remains limited [7].
Linkage studies have also identified a locus on 12p13 in
a kindred with the combination of extensive CVD and
elevated plasma low-density lipoprotein (LDL) cholesterol
levels and osteoporosis. The linkage interval contained six
annotated genes, including LDL-receptor related protein 6
(LRP6). The latter is an integral component of the Wnt
signaling pathway, which is involved in vascular develop-
ment and remodelling but also plays a role in the regulation
of glucose and lipid metabolism [9]. Common variants in
LRP6 have been associated with LDL metabolism in
humans [10, 11].
To increase the power to detect more commonly occurring
shared genetic loci, linkage analysis has been performed with
data derived from several families. These studies have resulted
in the identification of genetic variations in three genes
involved in atherosclerosis: arachidonate 5-lipoxygenase-
activating protein (ALOX5AP) and leukotriene A4 hydrolase
(LTA4H), both of which are pro-inflammatory cytokines, and
LDL receptor-related protein 8 (LRP8), also known as apoE
receptor 2 (APOER2), which is mainly expressed in the brain
[12, 13]. The relative contribution of these loci to athero-
sclerosis in replication studies remains modest, with typical
odds ratios no larger than 1.5 [12].
In recent years, numerous genome-wide association
(GWA) studies with CVD as the outcome have been
published. These studies primarily focus on populations,
rather than on families, and are carried out under the
assumption that common variants are shared by subjects
with a pre-specified phenotype. In this review, we provide
an update of the loci identified in GWA studies for CVD.
Of note, a total of nine loci identified in the six GWA
studies focusing on stroke have been poorly replicated and
are not discussed. Only the 9p21 locus has been found in all
the stroke GWA studies. The other eight loci (2q33, 4q25,
8q12, 11q12, 12q13, 14q22, 16q22, and 22q13) show
inconsistent results between the different studies and
warrant further validation [14]. To date, no GWA study
on peripheral artery disease (PAD) has been conducted. For
these reasons, this review focuses on loci discovered in
GWA studies with CAD as outcome (Fig. 1). In addition,
we discuss the possible current implications for biology and
clinical medicine as a result of the discovery of these loci.
GWA Studies
The rationale behind GWA studies is the “common disease,
common variant” hypothesis in which a limited number of
genetic variants with a high frequency (typically above 5%)
in the general population contribute to susceptibility for
disease [15]. GWA studies became possible because of two
Fig. 1 Proposed sites of action
for the proteins involved in the
pathogenesis of atherosclerosis:
liver, vessel wall, plaque and
thrombus
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major advances in genetics and technology. First, there was
the identification of almost 10 million common SNPs with
a minimum minor allele frequency of 5% in the HapMap
project and the notion that a large number of these SNPs are
in linkage disequilibrium (LD) [15, 16]. Because of these LD
blocks, a reduced number of SNPs provide complete whole
genome coverage [16]. Second, the development of DNA
microarrays for genotyping large numbers of SNPs and the
great reduction in their price have facilitated the inves-
tigation of large cohorts of patients and controls. The
first-generation GWA studies used a microsatellite
marker approach covering the genome by 400 unique
microsatellite markers [4]. Currently, microarrays are
available with more than 1 million SNPs. In addition,
microarrays were developed based on a candidate gene
approach, such as the IBC CardioChip (Illumina, San
Diego, CA) [17]. These have the advantage of a denser
SNP profile per locus, facilitating fine mapping, but the
disadvantage is that these often fail to find signals in loci
not previously associated with the phenotype.
Major GWA Studies in CVD and Implications
for Vascular Biology
Until recently, GWA studies with CAD as the major
outcome variable comprising more than 28,000 CAD cases
and 65,000 controls had identified 13 unique loci [18••,
19]. The recently published Global Lipids Consortium
study in 24,607 cases with CAD and 66,197 controls added
another four unique loci associated with CAD [20••]. These
17 loci are summarized in Table 1. As expected, the effect
sizes are modest and in the same order of magnitude as the
results obtained in GWA studies for other disorders.
The 9p21 locus was the first novel locus associated with
CAD risk in a large case–control study in six independent
samples comprising more than 23,000 participants from
four white populations [21]. Two copies of the 9p21 risk
alleles are present in about 25% of the population and
convey a 60% increased risk for CAD as compared to the
common genotype [21, 22]. The minor risk alleles of SNPs
in the 9p21 region are found at a higher frequency in
patients with early compared to late onset CAD [21, 23–
25]. Variations in the 9p21 locus might mediate their effect
through modulation of platelet reactivity and vascular
stiffness [26, 27]. Additionally, the locus has also been
found to be associated with other diseases associated with
CVD, such as stroke, abdominal aneurysms, and type 2
diabetes [28]. However, variants in this locus are also
associated with ovarian cancer, acute lymphoblastic leuke-
mia, poor physical function in the elderly, glioma, malig-
nant melanoma, breast cancer, and pancreatic cancer,
suggesting an interesting chromosomal area harboring
genes involved in a number of different physiologic
processes [28, 29].
Although the chromosomal region of 9p21 contains a
number of genes such as cyclin-dependent kinase inhibitor
2A and 2B (CDKN2A, CDNK2B), methylthioadenosine
phosphorylase (MTAP), and ANRIL, a long non-coding
RNA, the disease-associated SNPs are located far away
from these genes, which makes it more difficult to find the
causal gene responsible for the observed signal in CVD
[30]. CDKN2A, CDKN2B, and MTAP are involved in the
regulation of the cell cycle by interfering with cell cycle
progression, but additionally they are key players in
physiologic processes including replicative senescence,
apoptosis, and stem cell renewal. Direct sequencing of the
chromosomal region did not reveal any causal variants that
could explain the observed association. Interestingly, no
association could be detected between the causal SNPs and
differential expression of these genes [31]. CDKN2A,
CDKN2B, and MTAP are expressed in human vasculature
and atherosclerotic plaques. In mice, deletion of the risk
interval of 9p21 was shown to result in decreased
expression of CDKN2A and CDKN2B [32]. Moreover,
aortic smooth muscle cells harvested from mice deficient in
9p21 were found to have increased proliferative capacity
[32]. Another finding was that the 9p21 knockout mice
gained significantly more weight than their control litter-
mates [32]. An association between the 9p21 risk variant
and body weight has not been observed in humans. Also,
the burden of atherosclerosis measured by fatty lesion
formation was similar in mutant and wild-type animals.
Risk variants in the 9p21 locus associate with gene
expression levels of ANRIL, a non-coding RNA that can
alter gene expression of neighboring genes by RNA
interference or gene silencing [33]. Whole blood RNA
expression revealed a positive association between expres-
sion of ANRIL with CDKN2A and CDKN2B [30]. ANRIL is
expressed in eight different splice variants depending on the
tissue type, which complicates the analysis of the 9p21 locus
[30]. In conclusion, the 9p21 locus illustrates the complexity
of gene identification studies using the GWA approach.
Another highly significant signal associated with both
cholesterol levels and the occurrence of CVD is locus 1p31
[34••]. Although several SNPs in this region were associ-
ated with these traits, fine mapping of the locus identified
the rs12740374, located in the intergenic noncoding region,
as the causative SNP [20••]. Individuals who are homo-
zygous carriers of the major allele have up to 16 mg/dL
(0.4 mmol/L) higher LDL cholesterol plasma levels as well
as a 40% increased risk of myocardial infarction when
compared to carriers homozygous for the minor allele [23,
24]. Three genes, sortilin1 (SORT1), cadherin (CELSR2),
and proline-serine rich coiled coil1 (PCSR1), are located in
the 1p31 region. Tissue expression analysis reveals a strong
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Odds ratio per risk
allele (95% CI)
Candidate genes Putative mechanism Reference
1 1p13 rs599839 77 1.13 (1.08–1.19) CELSR2, PSCR1,
SORT1
LDL mediated [19]
1p13 rs646776 81 1.19 (1.13–1.26) CELSR2, PSCR1,
SORT1
[23]
2 2p32 rs11206510 81 1.15 (1.10–1.210 PCSK9 LDL mediated [23]
3 1q41 rs3008621 72 1.10 (1.04–1.17) MIA3 Unknown [19]
1q41 rs17465637 72 1.14 (1.10–1.19) MIA3 [23]
4 2q33 rs6725887 14 1.17 (1.11–1.19) WDRI2 Unknown [23]
5 2q36 rs2972416 37 0.46 IRS1 Defective insulin signaling
and NO production
[20••]
6 3q22 rs9818870 15 1.15 (1.11–1.19) MRAS Adhesion signaling [50]
7 6p21.31 rs2814982 16 0.49 C6orf106 Unknown [20••]
8 6p24 rs12526453 65 1.12 (1.08–1.17) PHACTR1 Coronary calcification [23]
9 6q26–6q27 rs2048327 18 1.20 (1.13–1.28) LPA,LPAL2,
SLC22A3
Promotes atherothrombosis [41]
6q26–6q27 rs3127599 18 1.20 (1.13–1.28) LPA,LPAL2,
SLC22A3
[41]
6q26–6q27 rs7767084 18 1.20 (1.13–1.28) LPA,LPAL2,
SLC22A3
[41]
6q26–6q27 rs10755578 18 1.20 (1.13–1.28) LPA,LPAL2,
SLC22A3
[41]
6q26–6q27 rs3798220 2 1.47 (1.35–1.60) LPA,LPAL2,
SLC22A3
[45]
6q26–6q27 rs10455872 7 1.68 (1.43–1.98) LPA,LPAL2,
SLC22A3
[45]
10 7q32 rs4731702 48 0.59 KLF14 Unknown [20••]
11 8p22 rs1495741 22 2.85 NAT2 Unknown [20••]





9p21 rs4977574 56 1.29 (1.25–1.34) ANRIL, CDKN2A,
CDKN2B, MTAP
[23]
9p21 rs10757274 48 ANRIL, CDKN2A,
CDKN2B, MTAP
[21]
9p21 rs28383206 51 ANRIL, CDKN2A,
CDKN2B, MTAP
[21]
9p21 rs2383207 51 1.22 (1.13–1.33) ANRIL, CDKN2A,
CDKN2B, MTAP
[21]
9p21 rs107572378 47 1.25 (1.15–1.36) ANRIL, CDKN2A,
CDKN2B, MTAP
[29]
9p21 rs10116277 48 ANRIL, CDKN2A,
CDKN2B, MTAP
[29]
13 10q11 rs501120 84 1.11 (1.05–1.18) CXCL12 Neointima formation after
arterial injury,
[19]
10q11 rs1746048 84 1.17 (1.11–1.24) CXCL12 platelet activation in
atherosclerotic lesions
[19]
14 12q24 rs2259816 37 1.08 (1.05–1.11) HNF1A apoM-mediated HDL
modification
[50]
15 12q24 rs3184504 40 1.13 (1.11–1.19) SH2B3 Reduced anti-inflammatory
activity contributes
[57]
12q24 rs11065987 34 1.14 (1.10–1.19) SH2B3 to the progression of
plaques
[57]
16 16p13 rs1122608 75 1.15 (1.10–1.21) LDLR LDL-mediated [23]
17 21q22 rs9882601 13 1.20 (1.14–1.27) KCNHE2, MRPS6,
SLC5A3
Unknown [23]
apo—apolipoprotein; GWA—genome-wide association; HDL—high-density lipoprotein; LDL—low-density lipoprotein; NO—nitric oxide
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association with hepatic SORT1 and PSRC1 expression.
Rs12740374 creates a predicted binding site for C/EBPalpha
transcription factors [33]. As a consequence, the hepatic gene
expression of SORT1 will be altered. SORT1 encodes for the
sortilin protein, also known as neurotensin receptor, a protein
that functions as a multi-ligand sorting receptor. Two studies
have been published recently investigating the role of
sortilin1 in hepatic lipoprotein metabolism using different
mouse models with conflicting results. In one study, Sort1-
deficient mice showed a reduction in the secretion of
apolipoprotein B100 (apoB100)-containing lipoproteins from
the liver and a reduction in atherosclerosis, whereas over-
expression of SORT1 increased plasma cholesterol levels
[35]. In the second study, a different approach using specific
hepatic overexpression of SORT1 in the liver using
adenovirus-mediated gene transfer in humanized mouse
models revealed a marked decrease in plasma cholesterol
levels by 73%, change in LDL size toward larger particles,
and consequently a reduction in atherosclerosis [34]. A
second approach using small interfering RNA technology
revealed similar results. Currently, there is no explanation for
the conflicting laboratory data observed.
In the GWA studies, highly significant signals at 19p13
at the LDL receptor (LDLR) and 1p32 at the proprotein
convertase subtilisin/kexin type 9 (PCSK9) were found. Both
well-known proteins play an important role in LDL metab-
olism and are strongly associated with atherosclerosis risk
and demonstrate that GWA studies are indeed capable of
detecting genes that are related to CVD [36, 37]. Rare
variants in LDLR and PCSK9 result in the Mendelian forms
of familial hypercholesterolemia (FH). Clinically, FH mani-
fests in lipid accumulation in tendons (xanthomas), the cornea
(arcus lipoides), and arterial wall, resulting in accelerated
atherosclerosis and premature CVD [38, 39]. In untreated
heterozygous FH patients, about 50% of males and 30% of
females will develop CVD before the age of 60 years [40].
Another highly significant signal in GWA studies was on
locus 6q25.3-26. This region harbors the gene lipoprotein(a)
(LPA), which was also previously shown to be implicated in
atherosclerosis, and also the solute carrier family 22 member
3 (SLC22A3) and lipoprotein(a)-like 2 (LPAL2) genes [41].
Increased plasma Lp(a) levels are causally related to CVD
[42]. Lp(a) is a cholesterol-rich LDL particle with one
apoprotein(a) molecule attached to the apoB100 protein
[43]. Due to homology of the repeated kringle structure of
apo(a) with plasminogen, it has been suggested that Lp(a)
intervenes with the process of atherosclerosis through
involvement of fibrinolysis and, as a consequence, the
atherothrombotic processes. Plasma levels of Lp(a) are
strongly genetically determined by the number of kringle IV
repeats in the apo(a) protein, which has a heritability between
21% and 27% [44]. SNPs identified by GWA studies are
strongly associated to the kringle IV repeats and thus to
plasma Lp(a) levels [45]. A recent meta-analysis revealed that
plasma Lp(a) concentration is a stronger biomarker for risk
than the gene score based on above-mentioned SNPs [45].
Other loci that have been identified in the GWA studies are
less frequently studied. In some cases there is suggestive
evidence for a role in atherosclerosis. In the next section we
discuss the genes located in proximity of these identified loci.
The gene of interest on locus 10q11 is CXCL12/SDF1
(chemokine [C-X-C-motif] ligand 12/stromal cell-derived
factor-1). In patients with stable and unstable angina,
plasma levels of CXCL12 are lower compared to healthy
controls [46]. Interestingly, CXCL12 is expressed in
atherosclerotic lesions and is of importance for vascular
repair and remodelling [46]. Furthermore, it has a role in
neo-intimal formation after injury [47]. Blocking its
receptor CXCR4 in Apoe−/− or Ldlr−/− mice aggravates
diet-induced atherosclerosis by affecting neutrophil recruit-
ment machinery [48]. CXCL12 may promote atherothrom-
bosis by its effect on platelets. It stimulates platelet
adhesion to immobilized collagen and fibrinogen and
induces the release of various platelet chemokines, in
particular P-selectin. P-selectin plays an essential role in
the initial recruitment of leukocytes to the site of injury
during inflammatory processes such as atherosclerosis [49].
Additional evidence that genetic variation in CXCL12 is
associated with CVD risk is eagerly awaited.
The locus on 3q22 encodes the Ras-related protein M-Ras
(MRAS) gene. The lead SNP, rs9818870, is located in the 3′
untranslated region of MRAS in close proximity to a cluster
of miRNA binding sites [50]. MRAS is widely expressed in
all tissues, with high expression in the cardiovascular system
and brain [50, 51]. MRAS is a member of the RAS family of
small molecular-weight GTP binding molecules and is
involved in the phosphoinositide kinase-3/mitogen-activated
protein kinase (PI3K-MAPK) signaling pathways. The
authors who reported the locus suggest a role for MRAS in
adhesion signaling, which is important in the atherosclerotic
process. No direct clues can be found in the literature to
bolster this statement. Recently, rs9818870 was shown to be
significantly associated with MRAS gene expression in aortic
tissue of patients, confirming the previous findings [50, 52].
Additional functional studies are lacking.
Phosphatase and actin regulator 1 (PHACTR1) is an
inhibitor of protein phosphatase 1 (PP1), an enzyme that
dephosphorylates serine and threonine residues on a range
of proteins and resides near 6q26–27 [53]. PP1 is a
ubiquitously expressed protein and involved in a number
of physiologica processes such as protein kinase-A (PKA)
and protein kinase C (PKC) phosphorylation [53]. It is
interesting that in an independent GWA study for coronary
artery calcification in more than 10,000 participants from
six prospective cohort studies, PHACTR1 SNPs (along with
chromosome 9p21 SNPs) were associated with coronary
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artery calcification at genome-wide significance (C.J.
O'Donnell, NHBL Institute, personal communication).
Rare variants in hepatocyte nuclear factor 1 homeobox A
(HNF1A) on 12q24 locus result in Mendelian forms of
maturity onset diabetes of the young (MODY) [54]. In a
recent GWA study searching for loci predictive for type 2
diabetes, rs7957197 in HNF1A reached genome-wide
significance. HNF1A is transcription factor involved in
expression of genes involved in innate immunity, blood
coagulation and lipid and glucose metabolism [55].
For insulin receptor substrate 1 gene (IRS1) and SH2B
adaptor protein 3 (SH2B3), the evidence for a role in
atherosclerosis is much weaker. The rs2972146 SNP on
chromosome 2 is close to IRS1, a gene that has been shown
to be essential in insulin signaling. Genetic variants in IRS1
impaired insulin signaling in endothelial cells. As a
consequence, nitric oxide (NO) release by these cells is
decreased [56]. However, a relation between endothelial
dysfunction and genetic variants of IRS1 has not been
published so far. SH2B3 located near 12q24 is expressed in
human vascular endothelial cells, where it promotes
inflammation. The lead SNP, rs3184504, which results in
a missense change, could contribute to the progression of
plaque formation in coronary arteries, leading to myocardial
infarction by its induction of a pro-inflammatory state.
SH2B3 has previously been shown to be associated with
type 1 diabetes and celiac disease [57].
Finally, more evidence has to be generated to further
identify the suspected candidate genes at the following loci and
their association with atherosclerosis: 1q41 locus, melanoma
inhibitory activity family member 3 (MIA3); 2q33 locus, WD
repeat domain 12(WDR12); 7q32 locus, Kruppel-like factor
14 (KLF14); 8p32 locus, N-acetyltransferase 2 (NAT2) and
21q22 locus potassium voltage-gated channel subfamily H
member (KCNH2) [58].
Implications for Clinical Medicine
The identification of the current 17 common variants
associated with CVD risk has so far had little impact on
routine clinical medicine. However, unravelling the biological
role of the proteins in the process of atherosclerosis, as has
been done for the 1p13 locus, will probably lead to a better
understanding of the pathways involved in the pathophysiol-
ogy of CVD. In addition, these pathways might be targets for
development of future therapeutic compounds.
The findings so far cannot be directly translated into a
risk profile for an individual patient. In a risk score
comprising nine GWA study SNPs associated with early-
onset MI, including a 9p21 SNPs and three SNPs
associated with LDL cholesterol, a twofold difference in
risk for MI between extreme quintiles of scores was found
[23]. However, in a prospective cohort, there was no
improvement in risk discrimination by addition of the risk
alleles of 9p21 in men or women [59, 60].
Conclusions
In the past years, efforts to disentangle the genetics of
CVD based on GWA studies have resulted in the
identification of several common variants with moderate
effects. This has resulted in the identification of 17 loci.
Still, only part of the heritability of CVD is currently
explained. More of the missing heritability could be
discovered by efforts to identify novel SNPs and efforts
to fine map candidate loci [61]. Identification of novel
SNPs will occur through future GWA studies and meta-
analyses of the current studies. At least two large GWA
studies (Cardiogram and C4D) on CVD are near com-
pletion and fine mapping of existing candidate loci is
ongoing.
Nevertheless, even with the outcome of these efforts only a
modest part of the risk for CVDwill be explained.We expect that
a substantial part of the missing heritability will be explained by
rare variants with severe effects on the phenotype. Some rare
variants causing CVD could even be de novo mutations, as
recently found in mental retardation [62]. Others might be
detected by studying families with severe disease (defined by a
combination of very early-onset CVD and multiple affected
individuals per family), possibly by a combination of exclusion
linkage studies and next-generation sequencing.
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